How Autobio Diagnostics Compresses High-Throughput CLIA into a Compact Lab Workhorse

AutoLumo S900 – Fully Automated Chemiluminescent Immunoassay Analyzer for Clinical Laboratories

Clinical laboratories operating in tight spaces have long faced a trade-off: either invest in sprawling, high-volume analyzers or accept lower throughput with compact benchtop models. Autobio Diagnostics’ AutoLumo S900 challenges that calculation. It is a fully automated chemiluminescent immunoassay (CLIA) analyzer designed to fit into small- and medium-sized labs while delivering throughput that rivals larger systems.

The machine’s core engineering decisions reveal the logic behind its performance. It uses five-stage magnetic separation cleaning and non-contact vortex mixing to improve assay precision and reduce carryover risk. Random access testing and automated reagent handling cut hands-on time, while real-time system monitoring gives operators visibility into workflow without requiring constant oversight.

With a test menu spanning more than 150 assays—covering tumor markers, hormones, infectious diseases, cardiac markers, and TB-IGRA panels—the S900 positions itself as a general-purpose platform. It does not specialise in one discipline but instead consolidates multiple diagnostic streams into a single, automated workflow. For smaller hospitals and blood banks, this reduces the number of instruments needed on the floor.

The operational logic is straightforward: automate everything that does not require a human decision. The system handles reagent tracking, sample loading, and washing cycles internally. The touchscreen interface centralises control, but the real labour savings come from the machine’s ability to run continuously with minimal intervention. For labs that process moderate volumes but cannot staff around the clock, this changes scheduling economics.

Autobio Diagnostics, headquartered in Zhengzhou, is one of China’s largest in-vitro diagnostics manufacturers. The company produces a full range of reagents and analyzers, giving it an integrated supply-chain advantage. The S900 is designed to work with Autobio’s own reagent portfolio, which means procurement managers can source consumables and hardware from a single supplier. This bundling reduces logistical complexity for hospitals that value standardisation.

China’s diagnostics sector has moved rapidly from import dependence to domestic capability. Instruments like the S900 are not merely cheaper alternatives; they are engineered for the specific constraints of local healthcare infrastructure—smaller lab footprints, varied test volumes, and a need for reliability across temperature and humidity ranges. The machine’s multiple safety detection systems suggest fault tolerance was a priority, not an afterthought.

The AutoLumo S900 does not try to be the fastest analyzer on the market. Instead, it solves a different problem: how to bring high automation to laboratories where every square metre matters. That focus on fit rather than raw specs may prove more durable as healthcare systems globally look to optimise existing space rather than build new ones.

Why it matters:
For procurement managers and lab directors, the S900 represents a practical alternative to oversizing equipment for modest workloads. It reduces the number of instruments needed, simplifies reagent supply chains, and makes high-throughput CLIA accessible to facilities that were previously limited by floor plan. Autobio’s vertical integration also means reagent cost and availability are under domestic control.

View Product →